Premium
A novel injury site‐natural antibody targeted complement inhibitor protects against lung transplant injury
Author(s) -
Li Changhai,
Patel Kunal,
Tu Zhenxiao,
Yang Xiaofeng,
Kulik Liudmila,
Alawieh Ali,
Allen Patterson,
Cheng Qi,
Wallace Caroline,
Kilkenny Jane,
Kwon Jennie,
Gibney Barry,
Cantu Edward,
Sharma Ashish,
Pipkin Mauricio,
Machuca Tiago,
Emtiazjoo Amir,
Goddard Martin,
Holers V. Michael,
Nadig Satish,
Christie Jason,
Tomlinson Stephen,
Atkinson Carl
Publication year - 2021
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.16404
Subject(s) - medicine , antibody , complement system , complement c1q , immunology , lung transplantation , lung , transplantation , reperfusion injury , ischemia
Complement is known to play a role in ischemia and reperfusion injury (IRI). A general paradigm is that complement is activated by self‐reactive natural IgM antibodies (nAbs), after they engage postischemic neoepitopes. However, a role for nAbs in lung transplantation (LTx) has not been explored. Using mouse models of LTx, we investigated the role of two postischemic neoepitopes, modified annexin IV (B4) and a subset of phospholipids (C2), in LTx. Antibody deficient Rag1‐/‐ recipient mice were protected from LTx IRI. Reconstitution with either B4 or C2nAb restored IRI, with C2 significantly more effective than B4 nAb. Based on these information, we developed/characterized a novel complement inhibitor composed of single‐chain antibody (scFv) derived from the C2 nAb linked to Crry (C2scFv‐Crry), a murine inhibitor of C3 activation. Using an allogeneic LTx, in which recipients contain a full nAb repertoire, C2scFv‐Crry targeted to the LTx, inhibited IRI, and delayed acute rejection. Finally, we demonstrate the expression of the C2 neoepitope in human donor lungs, highlighting the translational potential of this approach.